Recently, Yichang Humanwell Pharmaceutical Co., Ltd received the "Drug Registration Certificate" for dexmedetomidine hydrochloride injection approved and issued by the State Drug Administration, marking the sale of another new product of the company.

　　It is reported that dexmedetomidine, an alpha 2-adrenergic receptor agonist developed by Orion Pharma (Finland) and Abott (USA), is used clinically for sedation during tracheal intubation and mechanical ventilation on patients undergoing general anesthesia.

　　Yichang Humanwell Pharmaceutical Co., Ltd submitted the application for registration of dexmedetomidine hydrochloride injection to the State Drug Administration in November 2015. Up to now, the cumulative investment of the product is about 5 million yuan. The acquisition of the registered approval of the injection will further expand the business scope of Yichang Humanwell Pharmaceutical co., Ltd in this subfield. The company will arrange the production and sale of the product according to market demand.